BTK and COVID-19: The promising clinical data of ibrutinib and acalabrutinib at inhibiting cytokine storm and improving lymphopenia in COVID-19 patients will likely promote further development of additional trials to expand the use of BTK inhibitors to sepsis and other infectious and inflammatory diseases.